

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Sciences Office of Biostatistics

## STATISTICAL REVIEW AND EVALUATION - ERRATA

CLINICAL STUDIES

NDA #:	NDA 217026		
Supplement #:	N/A		
Drug Name:	Trofinetide (ACP-2566)		
Indication(s):	Treatment of Rett syndrome (in adults and pediatric patients 2 years of age and older)		
Applicant:	Acadia Pharmaceuticals, Inc.		
Date(s):	Submission date: 7/12/2022, PDUFA date: 3/12/2023		
<b>Review Priority:</b>	Priority		
<b>Biometrics Division:</b>	Division of Biometrics I		
Statistical Reviewer:	Andrew N. Potter, PhD		
<b>Concurring Reviewers:</b>	James Hung, PhD		
Medical Division:	Division of Neurology I		
Clinical Team:	Michael Dimyan, MD		
Project Manager:	Brenda Reggettz, PharmD		

Errata for the original Statistics Review of 02/04/2023.

This Review contains corrections to several typos in the original statistics review dated 02/04/2023.

In Section 3.2.2, the description of the stratification factors for Study 003 is missing age group (5-10 years old, 11-15 years old, and 16-20 years old).

## Table 3 should have the final two rows deleted: Table 1: Patient Disposition / Primary Analysis (ACP-2566-003)

Subject Disposition - Randomized Analysis Set

	Placebo N=94	Trofinetide N=93	Total N=187
Completion Status, n(%)			
Completed the Study	85 (90.4)	70 (75.3)	155 (82.9)
Early Termination	9 (9.6)	23 (24.7)	32 (17.1)
Reason for Early Termination, n(%)			
Adverse Event	2 (2.1)	16 (17.2)	18 (9.6)
Lack of Efficacy	0	1 (1.1)	1 (<1)
Non-Compliance with Study Drug	0	4 (4.3)	4 (2.1)
Protocol Deviation	1 (1.1)	0	1 (<1)
Subject Withdrew Consent	1 (1.1)	1 (1.1)	2 (1.1)
Other	5 (5.3)	1 (1.1)	6 (3.2)
Marked as Dropout but Had a Week 12 Visit, n(%)			
- Completed the Study	<del>93 (98.9)</del>	<del>86 (92.5)</del>	<del>179 (95.7)</del>
- Early Termination with Week 12 Visit	1 (1.1)	7 (7.5)	<del>8 (4.3)</del>

The Reviewer's Note above Table 4 should state eight patients instead of seven.

On page 10, the sentence beginning "In the trofinetide arm, there were only three subjects;" should read "In the **placebo** arm, there were only three subjects[.]"

On page 26, the "6.7 point greater improvement" should read "4.7 point greater improvement."

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

-----

/s/

ANDREW N POTTER 03/10/2023 11:21:16 AM

HSIEN MING J HUNG 03/10/2023 11:25:16 AM